舒泌通胶囊联合盐酸坦索罗辛缓释胶囊治疗良性前列腺增生症的临床疗效观察

来源:用户上传      作者:林钿

　　摘 要 目的：观察舒泌通胶囊联合盐酸坦索罗辛缓释胶囊治疗良性前列腺增生症（BPH）的临床疗效。方法：将118例BPH患者随机分为治疗组和对照组各59例，治疗组口服舒泌通胶囊和盐酸坦索罗辛缓释胶囊，对照组仅口服盐酸坦索罗辛缓释胶囊，均连续治疗3个月，观察临床评价指标、临床疗效、中医证候积分和不良反应。结果：治疗组国际前列腺症状评分、生命质量评分等临床评价指标、临床疗效、中医证候积分均优于对照组（均P<0.05）。结论：舒泌通胶囊联合盐酸坦索罗辛缓释胶囊对改善BPH的尿频、尿急等症状临床疗效明显，不良反应少，值得临床进一步试验。
　　关键词 舒泌通胶囊 坦索罗辛 良性前列腺增生症 尿频 尿急
　　中图分类号：R286； R697.32 文献标志码：A 文章编号：1006-1533（2022）11-0025-04
　　引用本文 林钿. 舒泌通胶囊联合盐酸坦索罗辛缓释胶囊治疗良性前列腺增生症的临床疗效观察[J]. 上海医药， 2022， 43（11）： 25-28.
　　Clinical efficacy of Shumitong capsule combined with tamsulosin hydrochloride sustained-release capsule in the treatment of benign prostatic hyperplasia
　　LIN Dian（Department of Urology， Southern Theater General Hospital， Chinese People’s Liberation Army， Guangzhou 510010， China）
　　ABSTRACT Objective： To observe the clinical efficacy of Shumitong capsule combined with tamsulosin hydrochloride sustained-release capsule in the treatment of benign prostatic hyperplasia （BPH）. Methods： One hundred and eighteen patients with BPH were randomly divided into a treatment group and a control group with 59 cases each. The treatment group was treated with Shumitong capsule and tamsulosin hydrochloride sustained-release capsule while the control group only with tamsulosin hydrochloride sustained-release capsule. The treatment was lasted for 3 months and the clinical evaluation indexes， clinical efficacy， traditional Chinese medicine symptom score and adverse reactions were observed. Results： The clinical evaluation indexes such as international prostate symptom score and quality of life score， clinical efficacy and traditional Chinese medicine symptom score were better in the treatment group than the control group （all P<0.05）. Conclusion： Shumitong capsule combined with tamsulosin hydrochloride sustained-release capsule can improve the clinical efficacy of BPH and relief symptoms such as urinary frequency and urinary urgency with few adverse reactions and is worthy of further clinical trials.
　　KEY WORDS Shumitong capsule； tamsulosin； BPH； urinary frequency； urinary urgency
　　良性前列腺增生（benign prostate hyperplasia， BPH）是男性老年人常的疾病。有关前列腺增生症的发病机制研究很多，但其病因至今仍然未明，目前年龄和有功能的睾丸被一致认为是前列腺增生发病的两个重要因素[1]。前列腺增生主要临床症状是尿频、尿急、尿不尽、排尿迟缓、尿流细小无力、排尿困难等，有合并充血炎症时可能会尿痛，严重时可出现尿潴留，长期排尿不畅则会引起肾积水，肾功能不全等全身症状。目前治疗该病常用的药物有a受体阻滞剂、5a-还原酶抑制剂、植物药类、M受体拮抗剂等。本研究采取高选择性a1-受体阻滞剂（盐酸坦索罗辛）联合中成药舒泌通胶囊，观察其治疗BPH的临床疗效。
　　1 资料和方法
　　1.1 一般资料
　　选取2019年1月―2019年12月份我院泌尿外科门诊的118例BPH患者随机分为治疗组（n=59）和对照组（n=59）。治疗组：年龄57～86岁，平均（68.95±8.74）岁；病程2～8年，平均（4.98±1.93）年。对照组：年龄56～86岁，平均（70.63±8.89）岁；病程2～8年，平均（4.95±2.16）年。所有病例按照《吴阶平泌尿外科学》诊断标准[2]执行。两组一般资料比较差异无统计学意义（P>0.05），具有可比性。

nlc202207071733

转载注明来源:https://www.xzbu.com/6/view-15435654.htm